Fig. 4From: Aloperine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathwayPI3K/AKT/ mTOR signaling pathway, the target of ALO. A549 and H1299 cells were treated with indicated concentrations of ALO for 24 h, and then cells were lysed with RIPA buffer. The cell lysates were analyzed by Western blotting with the indicated antibodies. *P < 0.05, compared to the control group (0 mM, solvent ethanol); #P < 0.05, compared to the ALO group (0.4 mM or 0.3 mM). Data are from one experiment representative of three experiments. Two-tailed Student’s testBack to article page